Scars - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Scars - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Scars pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Scars: Overview
Scars form as part of the healing process after your skin has been cut or damaged. The skin repairs itself by growing new tissue to pull together the wound and fill in any gaps caused by the injury. Scar tissue is made primarily of a protein called collagen. Scars develop in all shapes and sizes. Some scars are large and painful, while some are barely visible. When a scar first develops on lighter skin, it’s usually pink or red. Over time, the pinkish color fades, and the scar becomes slightly darker or lighter than the color of the skin. In people with dark skin, scars often appear as dark spots. Sometimes scars itch, and they may be painful or tender.
'Scars - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Scars pipeline landscape is provided which includes the disease overview and Scars treatment guidelines. The assessment part of the report embraces, in depth Scars commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Scars collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Scars report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Scars Emerging Drugs
Further product details are provided in the report..
Scars: Therapeutic Assessment
This segment of the report provides insights about the different Scars drugs segregated based on following parameters that define the scope of the report, such as:
Scars: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Scars therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Scars drugs.
Scars Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Scars - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Scars pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Scars: Overview
Scars form as part of the healing process after your skin has been cut or damaged. The skin repairs itself by growing new tissue to pull together the wound and fill in any gaps caused by the injury. Scar tissue is made primarily of a protein called collagen. Scars develop in all shapes and sizes. Some scars are large and painful, while some are barely visible. When a scar first develops on lighter skin, it’s usually pink or red. Over time, the pinkish color fades, and the scar becomes slightly darker or lighter than the color of the skin. In people with dark skin, scars often appear as dark spots. Sometimes scars itch, and they may be painful or tender.
'Scars - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Scars pipeline landscape is provided which includes the disease overview and Scars treatment guidelines. The assessment part of the report embraces, in depth Scars commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Scars collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Scars R&D. The therapies under development are focused on novel approaches to treat/improve Scars.
This segment of the Scars report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Scars Emerging Drugs
- STP 705: Sirnaomics
- Botulinum toxin E: Bonti
Further product details are provided in the report..
Scars: Therapeutic Assessment
This segment of the report provides insights about the different Scars drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Scars
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Scars: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Scars therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Scars drugs.
Scars Report Insights
- Scars Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Scars drugs?
- How many Scars drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Scars?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Scars therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Scars and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sirnaomics
- Roche
- OliX Pharmaceuticals
- Bonti
- FirstString Research
- Cellastra
- Scarless Laboratories
- Hugel
- RXi Pharmaceuticals, Corp.
- Olix Pharmaceuticals, Inc.
- Lemonex
- Krystal Biotech, Inc.
- AiViva BioPharma, Inc.
- AdiSave Inc.
- STP 705
- RG 6354
- OLX 101A
- Botulinum toxin E
- ACT 1
- Research programme: anti-scarring gene therapy
- SLI F06
- BMT101
- RXI-109
- OLX10010
- LEM-S401
- KB301
- AIV001
Introduction
Executive Summary
Scars: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Scars – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Scars companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Scars Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
STP 705: Sirnaomics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
OLX 101A: OliX Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
LEM S401: Lemonex
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Scars Key Companies
Scars Key Products
Scars- Unmet Needs
Scars- Market Drivers and Barriers
Scars- Future Perspectives and Conclusion
Scars Analyst Views
Scars Key Companies
Appendix
Executive Summary
Scars: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Scars – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Scars companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Scars Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
STP 705: Sirnaomics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
OLX 101A: OliX Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
LEM S401: Lemonex
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Scars Key Companies
Scars Key Products
Scars- Unmet Needs
Scars- Market Drivers and Barriers
Scars- Future Perspectives and Conclusion
Scars Analyst Views
Scars Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Scars
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Scars
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Scars
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Scars
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
